Virus safety of intravenous immunoglobulin
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 333-344
Abstract
Patients with immunodeficiencies or some types of autoimmune diseases are dependent on safe therapy with intravenous immunoglobulins. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism, these procedures are grouped into three classes: partitioning, inactivation, and removal based on size. Because of current socioeconomic and ecological changes, emerging pathogens continue to be expected. Such pathogens may spread very quickly because of increased intercontinental traffic. Severe acute respiratory syndrome-coronavirus and the West Nile virus are recent examples. Currently, it is not possible to predict the impact such a pathogen will have on blood safety because the capacity for a globally coordinated reaction to such a threat is also evolving. The worst-case scenario would be the emergence of a transmissible, small, nonenveloped virus in the blood donor population. Examples of small nonenveloped viruses, which change host and tissue tropism, are discussed, with focus on parvoviridae. Although today’s immunoglobulins are safer than ever, in preparation for future challenges it is a high priority for the plasma industry to proactively investigate such viruses on a molecular and cellular level to identify their vulnerabilities.Keywords
This publication has 81 references indexed in Scilit:
- Design of a UV-C irradiation process for the inactivation of viruses in protein solutionsBiologicals, 2005
- Use of IGIV in the Treatment of Immune-Mediated Dermatologic DisordersJournal of Investigative Dermatology Symposium Proceedings, 2004
- Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU–E derived from peripheral blood CD34+ cellsTransfusion, 2001
- Human Intravenous Immunoglobulin Preparation and Virus Inactivation by Pasteurization and Solvent Detergent TreatmentPreparative Biochemistry & Biotechnology, 2000
- Removal of Viruses from Human Intravenous Immune Globulin by 35 nm NanofiltrationBiologicals, 1998
- Determination of Adequate Moisture Content for Efficient Dry-Heat Viral Inactivation in Lyophilized Factor VIII by Loss on Drying and by Near Infrared SpectroscopyBiologicals, 1998
- Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidantsBlood, 1995
- The Global Spread and Replacement of Canine Parvovirus StrainsJournal of General Virology, 1988
- Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiencyThe American Journal of Medicine, 1988
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981